Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
In a recent Form 4 filing with the Securities and Exchange Commission, Sera Prognostics , Inc. (NASDAQ:SERA), a $146 million market cap company that maintains a strong balance sheet with more cash than debt, reported that its General Counsel, Jackson Benjamin, executed a series of stock transactions involving the company’s Class A Common Stock.
On March 5, 2025, Benjamin acquired 34,590 shares of Class A Common Stock through restricted stock units (RSUs), which were granted at no cost. This acquisition increased his total holdings to 140,829 shares.
The following day, on March 6, 2025, Benjamin sold 2,285 shares at an average price of $4.16 per share, amounting to a total sale of approximately $9,505. This transaction was conducted to cover tax withholding obligations related to the vesting of RSUs, as mandated by the issuer’s policy.
Additionally, Benjamin acquired stock options on March 5, 2025, granting him the right to purchase 49,420 shares at an exercise price of $4.20 per share. These options will vest over four years, contingent upon his continued service to the company.
These transactions reflect the ongoing management of equity incentives by Sera Prognostics’ executive team.
In other recent news, Sera Prognostics has made several significant announcements impacting its financial and research activities. The company has terminated its "at-the-market" stock offering, which was initially planned to raise up to $50 million through TD Securities. This decision halts their current capital-raising activities, with the potential for future offerings pending a new prospectus. In contrast, Sera Prognostics has launched a public stock offering aimed at expanding its U.S. commercial operations, preparing for EU growth, and pursuing FDA approval for its PreTRM test. This offering is managed by Jefferies, TD Cowen, William Blair, and RBC Capital Markets, and includes an option for underwriters to purchase additional shares.
Additionally, Sera Prognostics has announced that the Society for Maternal Fetal Medicine has published an abstract of the PRIME study results, which focus on improving neonatal outcomes through prematurity risk assessment and clinical interventions. These findings will be presented in detail at the SMFM 2025 Pregnancy Meeting. Following this, the company plans to host a conference call and webcast to discuss the study’s outcomes further. These developments reflect the company’s ongoing efforts to advance its research and market presence, providing investors with updates on both its financial strategies and scientific advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.